GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet.

The gut hormone gastric inhibitory polypeptide (GIP) plays a key role in glucose homeostasis and lipid metabolism. This study investigated the effects of administration of a stable and specific GIP receptor antagonist, (Pro(3))GIP, in mice previously fed a high-fat diet for 160 days to induce obesity and related diabetes. Daily intraperitoneal injection of (Pro(3))GIP over 50 days significantly decreased body weight compared with saline-treated controls, with a modest increase in locomotor activity but no change of high-fat diet intake. Plasma glucose, glycated hemoglobin, and pancreatic insulin were restored to levels of chow-fed mice, and circulating triglyceride and cholesterol were significantly decreased. (Pro(3))GIP treatment also significantly decreased circulating glucagon and corticosterone, but concentrations of GLP-1, GIP, resistin, and adiponectin were unchanged. Adipose tissue mass, adipocyte hypertrophy, and deposition of triglyceride in liver and muscle were significantly decreased. These changes were accompanied by significant improvement of insulin sensitivity, meal tolerance, and normalization of glucose tolerance in (Pro(3))GIP-treated high-fat-fed mice. (Pro(3))GIP concentrations peaked rapidly and remained elevated 24 h after injection. These data indicate that GIP receptor antagonism using (Pro(3))GIP provides an effective means of countering obesity and related diabetes induced by consumption of a high-fat, energy-rich diet.

[1]  N. Irwin,et al.  Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets , 2007, Diabetologia.

[2]  N. Irwin,et al.  Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice , 2007, Diabetologia.

[3]  C. Mcintosh,et al.  Activation of Lipoprotein Lipase by Glucose-dependent Insulinotropic Polypeptide in Adipocytes , 2007, Journal of Biological Chemistry.

[4]  Tanya Hansotia,et al.  Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. , 2007, The Journal of clinical investigation.

[5]  D. Drucker.  The role of gut hormones in glucose homeostasis. , 2007, The Journal of clinical investigation.

[6]  Yuichiro Yamada,et al.  Pancreatic and Extrapancreatic Effects of Gastric Inhibitory Polypeptide , 2006, Diabetes.

[7]  Huan‐Xin Chen,et al.  Effects of glucose-dependent insulinotropic peptide on behavior , 2006, Peptides.

[8]  B. Corkey,et al.  Glucose‐Dependent Insulinotropic Polypeptide Modulates Adipocyte Lipolysis and Reesterification , 2006, Obesity.

[9]  A. Mari,et al.  Mechanisms of Recovery From Type 2 Diabetes After Malabsorptive Bariatric Surgery , 2006, Diabetes.

[10]  J. Holst,et al.  Prohormone Convertase 1/3 Is Essential for Processing of the Glucose-dependent Insulinotropic Polypeptide Precursor* , 2006, Journal of Biological Chemistry.

[11]  T. Oshitari,et al.  Effect of combined antisense oligonucleotides against high-glucose- and diabetes-induced overexpression of extracellular matrix components and increased vascular permeability. , 2006, Diabetes.

[12]  J. Holst,et al.  Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs , 2006, Diabetologia.

[13]  P. Stewart,et al.  Mechanisms of Disease: selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 as a novel treatment for the metabolic syndrome , 2005, Nature Clinical Practice Endocrinology &Metabolism.

[14]  Yuichiro Yamada,et al.  Gastric inhibitory polypeptide modulates adiposity and fat oxidation under diminished insulin action. , 2005, Biochemical and biophysical research communications.

[15]  R. Thieringer,et al.  11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice , 2005, The Journal of experimental medicine.

[16]  C. Bailey,et al.  Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. , 2005, Diabetes.

[17]  P. Pilz,et al.  Lack of the metabotropic glutamate receptor subtype 7 selectively impairs short-term working memory but not long-term memory , 2004, Behavioural Brain Research.

[18]  M. Gagner,et al.  The Early Effect of the Roux-en-Y Gastric Bypass on Hormones Involved in Body Weight Regulation and Glucose Metabolism , 2004, Annals of surgery.

[19]  C. Bailey,et al.  Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice , 1981, Diabetologia.

[20]  J. Brown,et al.  Gastric inhibitory polypeptide (GIP) and insulin in obesity: Increased response to stimulation and defective feedback control of serum levels , 1978, Diabetologia.

[21]  J. Brunová.  [Endocrine diseases and diabetes]. , 2004, Casopis lekaru ceskych.

[22]  R. Pederson,et al.  Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. , 2003, Endocrinology.

[23]  P. Flatt,et al.  Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential? , 2003, Neuropeptides.

[24]  J. Holst,et al.  Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. , 2003, The Journal of clinical endocrinology and metabolism.

[25]  J. Bełtowski.  Adiponectin and resistin--new hormones of white adipose tissue. , 2003, Medical science monitor : international medical journal of experimental and clinical research.

[26]  R. Pederson,et al.  Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. , 2003, Endocrinology.

[27]  D. Hörsch,et al.  Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells. , 2002, The Journal of endocrinology.

[28]  Yuichiro Yamada,et al.  Inhibition of gastric inhibitory polypeptide signaling prevents obesity , 2002, Nature Medicine.

[29]  P. Flatt,et al.  Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide. , 2002, Biochemical and biophysical research communications.

[30]  Simon C Watkins,et al.  Skeletal muscle lipid content and insulin resistance: evidence for a paradox in endurance-trained athletes. , 2001, The Journal of clinical endocrinology and metabolism.

[31]  A. Häkkinen,et al.  Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. , 2000, Diabetes.

[32]  G. Shulman,et al.  On Diabetes: Insulin Resistance Cellular Mechanisms of Insulin Resistance , 2022 .

[33]  M. Wolfe,et al.  GIP biology and fat metabolism. , 1999, Life sciences.

[34]  M. Wolfe,et al.  Functional GIP receptors are present on adipocytes. , 1998, Endocrinology.

[35]  J. Fletcher,et al.  Investigations into the actions of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1(7-36)amide on lipoprotein lipase activity in explants of rat adipose tissue. , 1995, The Journal of nutrition.

[36]  J. Holst,et al.  Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans , 1994, Diabetes.

[37]  M. Brownstein,et al.  Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. , 1993, Endocrinology.

[38]  K. Petersen,et al.  Insulin Resistance in Type 2 Diabetes , 2016 .

[39]  P. Flatt,et al.  The effect of energy source and feeding level on the hormones of the entero-insular axis and plasma glucose in the growing pig , 1991, British Journal of Nutrition.

[40]  V. Marks,et al.  Effect of the entero-pancreatic hormones, gastric inhibitory polypeptide and glucagon-like polypeptide-1(7-36) amide, on fatty acid synthesis in explants of rat adipose tissue. , 1991, The Journal of endocrinology.

[41]  J. Pickup,et al.  Textbook of Diabetes , 1991 .

[42]  C. Bailey,et al.  Effects of diets rich in sucrose, coconut fat and safflowerseed oil on the development of the obese hyperglycaemic (ob/ob) syndrome in mice. , 1990, Diabetes research.

[43]  V. Marks,et al.  Immunoreactive gastric inhibitory polypeptide and K cell hyperplasia in obese hyperglycaemic (ob/ob) mice fed high fat and high carbohydrate cafeteria diets. , 1986, Acta endocrinologica.

[44]  G. Bray,et al.  Role of adrenal glands in the development of abnormal glucose and insulin homeostasis in genetically obese (ob/ob) mice. , 1986, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[45]  V. Marks,et al.  Plasma immunoreactive gastric inhibitory polypeptide in obese hyperglycaemic (ob/ob) mice. , 1984, The Journal of endocrinology.

[46]  P. Cryer,et al.  Mechanisms of postprandial glucose counterregulation in man. Physiologic roles of glucagon and epinephrine vis-a-vis insulin in the prevention of hypoglycemia late after glucose ingestion. , 1983, The Journal of clinical investigation.

[47]  J. Holst,et al.  Diminished immunoreactive gastric inhibitory polypeptide response to a meal in newly diagnosed type I (insulin-dependent) diabetics. , 1983, The Journal of clinical endocrinology and metabolism.

[48]  V. Marks,et al.  Abnormalities of GIP in Spontaneous Syndromes of Obesity and Diabetes in Mice , 1983, Diabetes.

[49]  P. Giacomoni,et al.  Gastric inhibitory polypeptide release after oral glucose: relationship to glucose intolerance, diabetes mellitus, and obesity. , 1982, The Journal of clinical endocrinology and metabolism.

[50]  R. Eckel,et al.  Gastric Inhibitory Polypeptide Enhanced Lipoprotein Lipase Activity in Cultured Preadipocytes , 1979, Diabetes.

[51]  J. Dupré,et al.  Effects of Ingestion of Triglyceride or Galactose on Secretion of Gastric Inhibitory Polypeptide and on Responses to Intravenous Glucose in Normal and Diabetic Subjects , 1978, Diabetes.

[52]  T. McDonald,et al.  Inhibition of actions of glucagon in adipocytes by gastric inhibitory polypeptide. , 1976, Metabolism: clinical and experimental.

[53]  J. Brown,et al.  The insulinotropic action of gastric inhibitory polypeptide in the perfused isolated rat pancreas. , 1976, Endocrinology.

[54]  E. Mazzaferri,et al.  Gastric inhibitory polypeptide (GIP) stimulated by fat ingestion in man. , 1975, The Journal of clinical endocrinology and metabolism.

[55]  J. Stevens.  Determination of glucose by an automatic analyser. , 1971, Clinica chimica acta; international journal of clinical chemistry.